Skip to content
DataLookout
Menu

NCT05143996

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved at least 2 years 10 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates pushed to Dec 30, 2029 Show 8 more changesShow less
    • Primary endpoint(s) modified
    • Phase changed: Phase 1 → Phase 1/2
    • Enrollment increased: 60 → 275 participants
    • Eligibility criteria shortened, about 228 words
    • Trial sites expanded: 11 → 17 locations
    • Trial arms changed: 3 → 5
    • Study description expanded, about 97 words
    • Secondary endpoints shortened, about 3 words
  2. Minor Site contacts updated at 1 of 11 sitesv8
  3. Notable Primary completion date: Aug 2025 to Jan 2027
    • Study sites: 7 to 11
    • Study completion date: Nov 2025 to Jun 2027
    v7
  4. Minor Site details revised at 1 of 7 sitesv6
  5. Minor Site details revised at 5 of 7 sitesv4
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Site details revised at 1 of 7 sitesv3
  2. Notable Enrollment target: 9 to 60v2 Show 7 more changesShow less
    • Primary completion date: Jul 2022 to Aug 2025
    • Eligibility criteria shortened, about 286 words
    • Study sites: 4 to 7
    • Study completion date: Jul 2022 to Nov 2025
    • Study description expanded, about 103 words
    • Study arms: 1 to 3
    • Study title expanded, about 4 words
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of treatment emergent events (TEAEs)
Timeframe: 28 days
Cmax of CLN-049
Timeframe: Up to 13 weeks
Ctrough of CLN-049
Timeframe: 28 Days
Tmax of CLN-049
Timeframe: 28 Days
T1/2 of CLN-049
Timeframe: Up to 28 days
Efficacy of CLN-049
Timeframe: Up to 13 weeks

Arms and interventions

Part A - Single ascending dose (SAD) design of IV administered CLN-049Experimental

Patients with relapsed/refractory AML or MDS will receive CLN-049 via IV administration

Part B - Multiple ascending dose (MAD) design of IV administered CLN-049Experimental

Patients with relapsed/refractory AML or MDS will receive CLN-049 via IV administration

Part C - Multiple ascending dose (MAD) design of SC administered CLN-049Experimental

Patients with relapsed/refractory AML or MDS will receive CLN-049 via SC injection

Part D - Phase 2 Dose Optimization and ExpansionExperimental

Dose Optimization: patients will be randomized 1:1 to one of two dose regimens of CLN-049 via IV derived from doses tested during Part B (MAD-IV). Dose Expansion: patients will receive a single dose regimen of CLN-049 via IV as determined by Dose Optimization (RP2D).

Part E - Expansion of IV-administered CLN-049 in newly diagnosed AML patients with TP53 mutationsExperimental

Newly diagnosed, previously untreated AML patients with TP53 mutations will receive a single dose regimen of CLN-049 via IV as determined by Dose Optimization (RP2D).

Drugs: CLN-049

Sites

17 sites in 1 country